Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of linsitini...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 22; no. 12; p. 2897
Main Authors:	Macaulay, Valentine M, Middleton, Mark R, Eckhardt, S Gail, Rudin, Charles M, Juergens, Rosalyn A, Gedrich, Richard, Gogov, Sven, McCarthy, Sean, Poondru, Srinivasu, Stephens, Andrew W, Gadgeel, Shirish M
Format:	Journal Article
Language:	English
Published:	United States 15.06.2016
Subjects:	Adult Aged Aged, 80 and over Antigens, CD Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Dose-Response Relationship, Drug Erlotinib Hydrochloride - adverse effects Erlotinib Hydrochloride - pharmacokinetics Erlotinib Hydrochloride - therapeutic use Female Humans Imidazoles - adverse effects Imidazoles - pharmacokinetics Imidazoles - therapeutic use Lung Neoplasms - drug therapy Male Maximum Tolerated Dose Middle Aged Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazines - adverse effects Pyrazines - pharmacokinetics Pyrazines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Insulin - antagonists & inhibitors Receptors, Somatomedin - antagonists & inhibitors Young Adult
ISSN:	1078-0432, 1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!